Revisions for Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations | Registro Público Cubano de Ensayos Clínicos

The revisions let you track differences between multiple versions of a post.

To edit, publish or delete one of the revisions below, click on its saved date.

Published clinical_trials Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations has 2 revisions.

Revision		Status
Saved 19/07/2023 - 3:26pm by Gladys		current revision (published)
Saved 22/05/2021 - 6:24pm by Gladys		archived

Registered Trials

Registration process

About the RPCEC

Useful resources